Enforcement efforts and partnership with industry: A needed strategy addressing counterfeit drugs

Abstract

Despite some law enforcement successes, organizations engaged in counterfeiting continued manufacturing, distributing and selling a wide range of unsafe medicines during the past year. This article will identify some of these successes that were made possible due to a public–private partnerships, as well as some of the challenges facing patients around the world. It also outlines the activities of the Pharmaceutical Security Institute, which engages through member companies and independently in public–private efforts to combat the problem of counterfeit drugs. These efforts may serve as models for innovative public–private partnerships that may be effective in coordinated, global efforts to protect the safety of the drug supply.